Oncology | Phase II Developments | ISRAEL

Biosight

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs

Lead Product(s): Aspacytarabine

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Israel Biotech Fund

Deal Size: $19.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing March 11, 2020

Details:

Proceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

RedHill Biopharma Provides Update on Opaganib (Yeliva®)

Lead Product(s): Opaganib,Upamostat,Hydroxychloroquine Sulphate

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 11, 2020

Details:

Recruitment initiated in 2nd arm of Phase 1/2a study evaluating opaganib in combination with hydroxychloroquine in advanced cholangiocarcinoma.

BioLineRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide in Combination With Anti-PD-1

Lead Product(s): Motixafortide,Pembrolizumab,Irinotecan

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The patent will be valid until July 2036 with a possibility of up to five years patent term extension.

Can-Fite BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson

Lead Product(s): Namodenoson

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

The Phase III pivotal trial will evaluate the efficacy of its drug candidate Namodenoson in patients with advanced hepatocellular carcinoma.

BioLineRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Can...

Lead Product(s): Motixafortide,Pembrolizumab,Fluorouracil

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Patients receive Motixafortide monotherapy priming treatment for five days, followed by combination cycles of chemotherapy, KEYTRUDA® and Motixafortide until progression.

BioLineRx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe

Lead Product(s): Motixafortide,Pembrolizumab,Irinotecan

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Motixafortide is currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with Merck.

Can-Fite BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

Lead Product(s): Namodenoson

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

Can-Fite’s completed Phase II liver cancer study found that Namodenoson increased overall survival in HCC patients with Child Pugh B7.

Find

Find Oncology Drugs in Phase II Clinical Development in ISRAEL

Israel

A collaboration with SCORR Marketing

Product Type

Companies

Biosight

Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs

RedHill Biopharma

RedHill Biopharma Provides Update on Opaganib (Yeliva®)

BioLineRx

BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide in Combination With Anti-PD-1

Can-Fite BioPharma

Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson

BioLineRx

BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Can...

BioLineRx

BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe

Can-Fite BioPharma

Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer